Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 13/20 | 0.64 |
| ▸ | MMP2 | P08253 | 13/20 | 0.64 |
| ▸ | MMP9 | P14780 | 13/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29403984 | 1.00 | MMP1 (0.64) | MMP1MMP2MMP9MEN1AKR1B1 | |
| SCHEMBL4199528 | 1.00 | MMP1 (0.64) | MMP1MMP2MMP9MEN1AKR1B1 | |
| SCHEMBL30041332 | 1.00 | MMP1 (0.64) | MMP1MMP2MMP9MEN1AKR1B1 | |
| SCHEMBL9973849 | 0.91 | MMP1 (0.63) | MMP1MMP2MMP9MEN1AKR1B1 | |
| SCHEMBL30492916 | 0.90 | MMP1 (0.58) | MMP1MMP2MMP9MEN1AKR1B1 | |
| SCHEMBL10005257 | 0.89 | MMP1 (0.66) | MMP1MMP2MMP9MEN1AKR1B1 | |
| SCHEMBL29913807 | 0.89 | TRPM2 (0.62) | MMP1MMP2MMP9MEN1KMT2A | |
| SCHEMBL4670083 | 0.89 | TRPM2 (0.62) | MMP1MMP2MMP9MEN1KMT2A | |
| SCHEMBL5351229 | 0.89 | TRPM2 (0.62) | MMP1MMP2MMP9MEN1KMT2A | |
| SCHEMBL14227304 | 0.88 | BACE1 (0.56) | MMP1MMP2MMP9MEN1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558158-A1 | METHOD FOR INCREASING THE CONCENTRATION OF ONE OR MORE BIO-ACTIVES IN GRAINS | The Quaker Oats Company (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250154095-A1 | SYNTHESIS METHOD OF AVENANTHRAMIDE C | DONG-A UNIVERSITY RESEARCH FOUNDATION FOR INDUSTRY-ACADEMY COOPERATION (KR) | 2025-05-15 | — | — | US | disclosed |
| WO-2024020099-A1 | METHOD FOR INCREASING THE CONCENTRATION OF ONE OR MORE BIO-ACTIVES IN GRAINS | THE QUAKER OATS COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240023476-A1 | Method for Increasing the Concentration of one or more Bio-actives in Grains | THE QUAKER OATS COMPANY | 2024-01-25 | — | — | US | disclosed |
| WO-2023140435-A1 | METHOD FOR SYNTHESIZING AVENANTHRAMIDES C | 동아대학교 산학협력단 | 2023-07-27 | — | — | WO | disclosed |
| US-20230131993-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY | SYMRISE AG (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230129036-A1 | AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE | SYMRISE AG (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230129036-A1 | AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE | SYMRISE AG (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230131993-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY | SYMRISE AG (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230118467-A1 | COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L | SYMRISE AG (DE) | 2023-04-20 | — | — | US | disclosed |
| EP-1886662-A1 | Anti-microbial compounds for treating bad breath | Symrise GmbH & Co. KG (DE) | 2008-02-13 | — | — | EP | disclosed |
| EP-1886662-A1 | Anti-microbial compounds for treating bad breath | Symrise GmbH & Co. KG (DE) | 2008-02-13 | — | — | EP | disclosed |
| US-20080008660-A1 | Antimicrobially active compounds for treating bad breath | SYMRISE GMBH & CO. KG (DE) | 2008-01-10 | — | — | US | disclosed |
| US-20080008660-A1 | Antimicrobially active compounds for treating bad breath | SYMRISE GMBH & CO. KG (DE) | 2008-01-10 | — | — | US | disclosed |
| EP-1856030-A2 | STRUCTURAL ANALOGUES OF AVENANTHRAMIDES, THEIR USE IN COMPOSITIONS USEFUL IN THE TREATMENT OF DERMATOLOGICAL DISORDERS | RELIVIA SRL (IT) | 2007-11-21 | — | — | EP | disclosed |
| US-20070185038-A1 | Regulation of mammalian keratinous tissue using skin care actives | THE PROCTER & GAMBLE COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-20070185038-A1 | Regulation of mammalian keratinous tissue using skin care actives | THE PROCTER & GAMBLE COMPANY | 2007-08-09 | — | — | US | disclosed |
| WO-2007062957-A1 | MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING | SYMRISE GMBH & CO. KG (DE) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007041548-A2 | COMPOSITION FOR REGULATION OF MAMMALIAN KERATINOUS TISSUE | THE PROCTER & GAMBLE COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2006087393-A2 | STRUCTURAL ANALOGUES OF AVENANTHRAMIDES, THEIR USE IN COMPOSITIONS USEFUL IN THE TREATMENT OF DERMATOLOGICAL DISORDERS | RELIVIA S.R.L. (IT) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154095-A1 | SYNTHESIS METHOD OF AVENANTHRAMIDE C | OAT, MCCC2, OTC | MMP1 4045/4885MMP2 1989/4885MMP9 3065/4885 |
| US-20230129036-A1 | AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE | HPD, CYP4A22, PAH | MMP1 1164/4885MMP2 696/4885MMP9 1840/4885 |
| US-20230131993-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY | OAT, PIGS, HLA-A | MMP1 3885/4885MMP2 3658/4885MMP9 2745/4885 |
| US-20070185038-A1 | Regulation of mammalian keratinous tissue using skin care actives | CUTA, KDM7A, KDM2A | MMP1 937/4885MMP2 1084/4885MMP9 1741/4885 |
| US-20080008660-A1 | Antimicrobially active compounds for treating bad breath | CAT, LPO, GPX1 | MMP1 1177/4885MMP2 1501/4885MMP9 1691/4885 |
| US-20230118467-A1 | COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L | TACR1, NPSR1, TACR2 | MMP1 1370/4885MMP2 2460/4885MMP9 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.